
Anito-cel could be ‘significant’ treatment for myeloma
Biotechnology company Arcellx has announced positive data from the Phase II study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM). Results from the iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population,… Read More








